• Ascentage Pharma Group International released new clinical data from multiple ongoing trials slated for presentation at the ASCO Annual Meeting on May 29–June 2, 2026, including three selected for rapid oral sessions.
• Early results from a study combining its BCR-ABL inhibitor olverembatinib with the immunotherapy blinatumomab showed deepened responses in hard-to-treat Philadelphia chromosome-positive leukemias, with side effects described as manageable.
• Updated findings from a China study positioned olverembatinib as an effective second-line option for chronic-phase CML, supporting broader use beyond the highest-risk mutation setting.
• Pediatric data for the MDM2-p53 inhibitor alrizomadlin, alone or with the Bcl-2 inhibitor lisaftoclax, showed acceptable tolerability with signs of tumor shrinkage and disease control, backing continued development in pediatric solid tumors.
• Pipeline execution also centered on two global Phase 3 registrational programs now in progress, including POLARIS-2 for olverembatinib in chronic-phase CML and GLORA for lisaftoclax in CLL/SLL, a setup that could expand the company’s late-stage value drivers if readouts support filing plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605212000PRIMZONEFULLFEED9725146) on May 22, 2026, and is solely responsible for the information contained therein.